Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine work‐up of tumours
Katrin S. Huettl(Robert Bosch Hospital), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Fina Climent, Annette M. Staiger(Robert Bosch Hospital), Falko Fend(Universitätsklinikum Tübingen), Georg Lenz(Charité - Universitätsmedizin Berlin), Alexandar Tzankov(University of Basel), Andreas Rosenwald, José‐Tomás Navarro(Universitat Autònoma de Barcelona), Fabian Frontzek(Spinal Cord Injury BC), Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Josep Castellví(Universitat Autònoma de Barcelona), Stefan Dirnhofer(University of Basel), Ioannis Anagnostopoulos(Humboldt-Universität zu Berlin), Maria João Baptista(Josep Carreras Leukaemia Research Institute), Wolfgang Hartmann(University Hospital Münster), Heike Horn(Robert Bosch Hospital), John R. Goodlad(National Health Service)
Cited by 7
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k